Review of EMERALD Subgroup Analysis Data From SABCS 2023
Subgroup analyses from the EMERALD trial show that oral SERD elacestrant may outperform standard endocrine therapy in metastatic breast cancer patients with bone or visceral metastases who previously received CDK4/6 inhibitors.
EP: 1.Patient Case: A 56-Year-Old Woman with HR+/HER2- Metastatic Breast Cancer and Visceral Metastases
EP: 2.Unmet Needs in the Treatment of Patients With Metastatic Breast Cancer With Visceral Metastases
EP: 3.The Impact of Biomarkers in Clinical Decision-Making and Emergent Agents in HR+/HER2- Metastatic Breast Cancer
EP: 4.Review of EMERALD Subgroup Analysis Data From SABCS 2023
EP: 5.Selecting a Second-Line Therapy for a Patient With HR+/HER2- mBC After Progression on ET + CDK4/6i Therapy
EP: 6.Management Approaches for HR+/HER2- mBC Based on Metastasis Location and Disease Burden
EP: 7.Management of Adverse Events in Patients With HR+/HER2- Metastatic Breast Cancer
EP: 8.Future Directions in the Treatment of Patients With HR+/HER2- Metastatic Breast Cancer
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Survival and Safety Outcomes Factor into Use of Sacituzumab Govitecan in HR+ Breast Cancer
March 29th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor–positive breast cancer in the first article of a 2-part series.
Read More
